Fulgent Genetics, Inc. (FLGT) Stock Grade

About Fulgent Genetics, Inc.'s fundamentals

Fulgent Genetics is a diagnostics and research company with a market capitalization of $808.5 million that generated 13.8% year-over-year revenue growth in its latest period. However, the company is currently unprofitable, operating with an -18.8% net margin and reporting a net loss in its most recent annual statement, which also means traditional valuation metrics like P/E ratio and return on equity are not applicable. The company does not pay a dividend, indicating reinvestment of any available capital into operations rather than shareholder distributions.